Symbols / VERA Stock $34.26 +1.81% Vera Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
VERA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Marshall W. Fordyce M.D.
Exch · Country NGM · United States
Market Cap 2.46B
Enterprise Value 1.94B
Income -368.95M
Sales —
FCF (ttm) -179.42M
Book/sh 6.97
Cash/sh 8.31
Employees 339
Insider 10d —
IPO May 14, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -9.01
PEG —
P/S —
P/B 4.92
P/C —
EV/EBITDA -5.07
EV/Sales —
Quick Ratio 13.30
Current Ratio 13.64
Debt/Eq 15.39
LT Debt/Eq —
EPS (ttm) -5.54
EPS next Y -3.80
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-04
Earnings (prior) 2026-05-07
ROA -38.90%
ROE -71.32%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 71.78M
Shs Float 52.06M
Insider Own 0.87%
Instit Own 110.51%
Short Float 17.19%
Short Ratio 10.86
Short Interest 10.83M
52W High 56.05
vs 52W High -38.88%
52W Low 19.07
vs 52W Low 79.69%
Beta 0.95
Impl. Vol. 45.48%
Rel Volume 0.78
Avg Volume 1.16M
Volume 899.03K
Target (mean) $78.00
Tgt Median $82.00
Tgt Low $35.00
Tgt High $110.00
# Analysts 14
Recom Strong_buy
Prev Close $33.65
Price $34.26
Change 1.81%
About

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$78.00
Mean price target
2. Current target
$34.26
Latest analyst target
3. DCF / Fair value
$-44.99
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$34.26
Low
$35.00
High
$110.00
Mean
$78.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-15 main Evercore ISI Group Outperform → Outperform $91
2026-03-11 up Wolfe Research Peer Perform → Outperform $88
2026-03-02 main HC Wainwright & Co. Buy → Buy $110
2025-12-19 main B of A Securities Buy → Buy $66
2025-12-19 main Goldman Sachs Buy → Buy $95
2025-12-19 main JP Morgan Overweight → Overweight $96
2025-12-11 main Wedbush Neutral → Neutral $33
2025-12-08 main Evercore ISI Group Outperform → Outperform $97
2025-12-05 main TD Cowen Buy → Buy $73
2025-11-10 main HC Wainwright & Co. Buy → Buy $90
2025-11-07 main JP Morgan Overweight → Overweight $52
2025-10-16 init B of A Securities — → Buy $48
2025-08-07 main JP Morgan Overweight → Overweight $53
2025-08-04 down Wolfe Research Outperform → Peer Perform —
2025-06-02 main Scotiabank Sector Outperform → Sector Outperform $65
2025-06-02 main HC Wainwright & Co. Buy → Buy $85
2025-05-12 main Scotiabank Sector Outperform → Sector Outperform $55
2025-05-07 main Wedbush Neutral → Neutral $26
2025-05-07 main Cantor Fitzgerald Overweight → Overweight $100
2025-03-04 main JP Morgan Overweight → Overweight $71
News
RSS: Latest VERA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-12 FORDYCE MARSHALL Chief Executive Officer — 18,500 $36.64 $679,747
2026-04-14 FORDYCE MARSHALL Chief Executive Officer — 22,951 $43.66 $1,011,051
2026-03-23 WRIGHT-MITCHELL JANE Officer — 42,403 $0.00 $0
2026-03-13 YOUNG JOSEPH R Officer — 10,000 $3.94 $39,396
2026-02-23 TURNER WILLIAM DONALD Officer — 2,187 $41.98 $91,819
2026-02-23 FORDYCE MARSHALL Chief Executive Officer — 16,925 $41.98 $710,578
2026-02-23 YOUNG JOSEPH R Officer — 3,117 $41.98 $130,864
2026-02-23 GRANT SEAN Chief Financial Officer — 4,949 $41.98 $207,778
2026-02-23 BRENNER ROBERT Officer — 2,151 $41.98 $90,307
2026-02-23 JOHNSON DAVID LEE Chief Operating Officer — 2,579 $41.98 $108,276
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
315.47
+88.71%
167.17
+63.87%
102.01
+12.22%
90.90
Research And Development
215.26
+70.61%
126.17
+61.29%
78.22
+13.38%
68.99
Selling General And Administration
100.22
+144.44%
41.00
+72.35%
23.79
+8.57%
21.91
General And Administrative Expense
100.22
+144.44%
41.00
+72.35%
23.79
+8.57%
21.91
Other Gand A
100.22
+144.44%
41.00
+72.35%
23.79
+8.57%
21.91
Total Expenses
315.47
+88.71%
167.17
+63.87%
102.01
+12.22%
90.90
Operating Income
-315.47
-88.71%
-167.17
-63.87%
-102.01
-12.22%
-90.90
Total Operating Income As Reported
-315.47
-88.71%
-167.17
-63.87%
-102.01
-12.22%
-90.90
EBITDA
-291.62
-101.93%
-144.42
-56.66%
-92.18
-4.68%
-88.06
Normalized EBITDA
-291.62
-101.93%
-144.42
-56.66%
-92.18
-5.65%
-87.25
Reconciled Depreciation
0.47
+345.71%
0.10
+400.00%
0.02
+102.48%
-0.85
EBIT
-292.08
-102.10%
-144.52
-56.74%
-92.20
-4.70%
-88.06
Total Unusual Items
—
—
-0.05
+94.19%
-0.81
Total Unusual Items Excluding Goodwill
—
—
-0.05
+94.19%
-0.81
Special Income Charges
—
—
—
0.00
Restructuring And Mergern Acquisition
—
—
—
—
Net Income
-299.62
-96.92%
-152.15
-58.50%
-95.99
-7.79%
-89.06
Pretax Income
-299.61
-96.92%
-152.15
-58.50%
-95.99
-7.79%
-89.06
Net Non Operating Interest Income Expense
16.95
+29.49%
13.09
+212.14%
4.19
+453.17%
0.76
Interest Expense Non Operating
7.53
-1.25%
7.63
+101.43%
3.79
+281.65%
0.99
Net Interest Income
16.95
+29.49%
13.09
+212.14%
4.19
+453.17%
0.76
Interest Expense
7.53
-1.25%
7.63
+101.43%
3.79
+281.65%
0.99
Interest Income Non Operating
24.48
+18.18%
20.71
+159.61%
7.98
+355.94%
1.75
Interest Income
24.48
+18.18%
20.71
+159.61%
7.98
+355.94%
1.75
Other Income Expense
-1.09
-156.28%
1.94
+5.74%
1.83
+67.89%
1.09
Other Non Operating Income Expenses
-1.09
-156.28%
1.94
+5.74%
1.83
-3.63%
1.90
Gain On Sale Of Security
—
—
-0.05
+94.19%
-0.81
Gain On Sale Of Business
—
—
—
0.00
Tax Provision
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Rate For Calcs
0.00
-100.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
+100.00%
-0.17
Net Income Including Noncontrolling Interests
-299.62
-96.92%
-152.15
-58.50%
-95.99
-7.79%
-89.06
Net Income From Continuing Operation Net Minority Interest
-299.62
-96.92%
-152.15
-58.50%
-95.99
-7.79%
-89.06
Net Income From Continuing And Discontinued Operation
-299.62
-96.92%
-152.15
-58.50%
-95.99
-7.79%
-89.06
Net Income Continuous Operations
-299.62
-96.92%
-152.15
-58.50%
-95.99
-7.79%
-89.06
Normalized Income
-299.62
-96.92%
-152.15
-58.50%
-95.99
-8.57%
-88.42
Net Income Common Stockholders
-299.62
-96.92%
-152.15
-58.50%
-95.99
-7.79%
-89.06
Diluted EPS
-4.66
-69.45%
-2.75
-22.22%
-2.25
+32.84%
-3.35
Basic EPS
-4.66
-69.45%
-2.75
-22.22%
-2.25
+32.84%
-3.35
Basic Average Shares
64.23
+16.10%
55.33
+29.55%
42.71
+60.73%
26.57
Diluted Average Shares
64.23
+16.10%
55.33
+29.55%
42.71
+60.73%
26.57
Diluted NI Availto Com Stockholders
-299.62
-96.92%
-152.15
-58.50%
-95.99
-7.79%
-89.06
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
734.73
+12.06%
655.68
+273.51%
175.55
+33.56%
131.44
Current Assets
728.88
+11.93%
651.22
+278.56%
172.02
+36.85%
125.70
Cash Cash Equivalents And Short Term Investments
714.59
+11.51%
640.85
+298.75%
160.72
+40.18%
114.65
Cash And Cash Equivalents
354.73
+282.88%
92.65
+102.81%
45.68
+5.11%
43.46
Cash Equivalents
350.11
+290.19%
89.73
—
—
Cash Financial
4.62
+58.24%
2.92
—
—
Other Short Term Investments
359.86
-34.36%
548.21
+376.56%
115.03
+61.58%
71.19
Receivables
3.29
-12.93%
3.77
+636.91%
0.51
—
Accrued Interest Receivable
3.29
-12.93%
3.77
+636.91%
0.51
—
Prepaid Assets
8.47
+62.65%
5.21
-39.12%
8.56
-17.12%
10.33
Other Current Assets
2.54
+83.30%
1.38
-38.18%
2.24
+211.13%
0.72
Total Non Current Assets
5.85
+31.08%
4.46
+26.68%
3.52
-38.59%
5.74
Net PPE
3.30
-23.89%
4.33
+42.45%
3.04
-41.79%
5.22
Gross PPE
3.30
-23.89%
4.33
+42.45%
3.04
-41.79%
5.22
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
1.92
-42.97%
3.37
+14.34%
2.95
-42.99%
5.17
Other Properties
1.37
+43.13%
0.96
+943.48%
0.09
+80.39%
0.05
Investments And Advances
—
—
—
0.06
Non Current Prepaid Assets
—
—
—
—
Other Non Current Assets
2.55
+1848.85%
0.13
-72.82%
0.48
-6.04%
0.51
Total Liabilities Net Minority Interest
130.21
+65.82%
78.53
+6.32%
73.86
+35.46%
54.53
Current Liabilities
53.45
+110.69%
25.37
+13.76%
22.30
-12.88%
25.60
Payables And Accrued Expenses
51.54
+132.84%
22.14
+11.42%
19.87
-13.45%
22.95
Payables
21.90
+177.86%
7.88
-39.57%
13.04
-11.69%
14.77
Accounts Payable
21.90
+185.69%
7.67
-31.06%
11.12
-7.28%
11.99
Current Accrued Expenses
29.64
+107.94%
14.25
+108.90%
6.82
-16.63%
8.18
Current Debt And Capital Lease Obligation
0.55
-62.98%
1.48
-39.12%
2.44
-7.90%
2.65
Current Capital Lease Obligation
0.55
-62.98%
1.48
-39.12%
2.44
-7.90%
2.65
Other Current Liabilities
1.37
-22.02%
1.75
—
—
Total Non Current Liabilities Net Minority Interest
76.76
+44.40%
53.16
+3.10%
51.56
+78.23%
28.93
Long Term Debt And Capital Lease Obligation
76.76
+44.40%
53.16
+3.67%
51.27
+79.02%
28.64
Long Term Debt
74.84
+47.65%
50.69
+1.62%
49.88
+101.04%
24.81
Long Term Capital Lease Obligation
1.92
-22.24%
2.47
+76.92%
1.40
-63.59%
3.83
Other Non Current Liabilities
—
—
—
—
Stockholders Equity
604.52
+4.74%
577.15
+467.59%
101.69
+32.22%
76.91
Common Stock Equity
604.52
+4.74%
577.15
+467.59%
101.69
+32.22%
76.91
Capital Stock
0.07
+10.94%
0.06
+45.45%
0.04
+57.14%
0.03
Common Stock
0.07
+10.94%
0.06
+45.45%
0.04
+57.14%
0.03
Preferred Stock
—
0.00
0.00
0.00
Share Issued
71.27
+12.13%
63.56
+42.98%
44.45
+59.89%
27.80
Ordinary Shares Number
71.27
+12.13%
63.56
+42.98%
44.45
+59.89%
27.80
Additional Paid In Capital
1,364.53
+31.46%
1,037.95
+152.85%
410.49
+41.44%
290.22
Retained Earnings
-760.87
-64.96%
-461.25
-49.22%
-309.10
-45.04%
-213.11
Gains Losses Not Affecting Retained Earnings
0.79
+100.00%
0.39
+56.57%
0.25
+212.05%
-0.22
Other Equity Adjustments
0.79
+100.00%
0.39
+56.57%
0.25
+212.05%
-0.22
Total Equity Gross Minority Interest
604.52
+4.74%
577.15
+467.59%
101.69
+32.22%
76.91
Total Capitalization
679.36
+8.21%
627.84
+314.25%
151.56
+49.00%
101.72
Working Capital
675.43
+7.92%
625.85
+318.01%
149.72
+49.57%
100.10
Invested Capital
679.36
+8.21%
627.84
+314.25%
151.56
+49.00%
101.72
Total Debt
77.31
+41.49%
54.64
+1.73%
53.71
+71.67%
31.29
Net Debt
—
—
4.20
—
Capital Lease Obligations
2.47
-37.53%
3.95
+3.13%
3.83
-40.84%
6.48
Net Tangible Assets
604.52
+4.74%
577.15
+467.59%
101.69
+32.22%
76.91
Tangible Book Value
604.52
+4.74%
577.15
+467.59%
101.69
+32.22%
76.91
Available For Sale Securities
—
—
—
0.06
Dueto Related Parties Current
0.00
-98.62%
0.22
-88.73%
1.93
-30.72%
2.78
Investmentin Financial Assets
—
—
—
0.06
Non Current Accrued Expenses
—
0.00
-100.00%
0.29
+0.00%
0.29
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-241.10
-79.02%
-134.68
-46.10%
-92.18
-36.37%
-67.60
Cash Flow From Continuing Operating Activities
-241.10
-79.02%
-134.68
-46.10%
-92.18
-36.37%
-67.60
Net Income From Continuing Operations
-299.62
-96.92%
-152.15
-58.50%
-95.99
-7.79%
-89.06
Depreciation Amortization Depletion
0.47
+345.71%
0.10
+400.00%
0.02
+102.48%
-0.85
Depreciation
—
—
-4.09
-382.98%
-0.85
Depreciation And Amortization
0.47
+345.71%
0.10
+400.00%
0.02
+102.48%
-0.85
Other Non Cash Items
4.11
+42.87%
2.87
+12.71%
2.55
-56.51%
5.86
Stock Based Compensation
37.93
+82.32%
20.80
+81.00%
11.49
+29.32%
8.89
Asset Impairment Charge
—
—
—
—
Operating Gains Losses
—
—
—
—
Unrealized Gain Loss On Investment Securities
—
—
0.05
-94.19%
0.81
Gain Loss On Sale Of PPE
—
—
—
0.00
Change In Working Capital
22.99
+764.36%
2.66
+145.69%
-5.82
-186.29%
6.75
Change In Prepaid Assets
-3.93
-500.41%
0.98
+467.05%
0.17
+102.11%
-8.18
Change In Payables And Accrued Expense
28.35
+659.09%
3.73
+220.95%
-3.09
-117.50%
17.64
Change In Accrued Expense
14.44
+100.92%
7.19
+424.51%
-2.21
-131.48%
7.04
Change In Payable
13.91
+502.84%
-3.45
-295.53%
-0.87
-108.23%
10.61
Change In Account Payable
13.91
+502.84%
-3.45
-295.53%
-0.87
-108.23%
10.61
Change In Other Current Assets
0.05
-85.47%
0.35
+233.97%
-0.26
-136.04%
-0.11
Change In Other Current Liabilities
-1.48
+38.39%
-2.41
+9.00%
-2.65
-1.65%
-2.60
Investing Cash Flow
194.29
+145.71%
-425.03
-977.91%
-39.43
+44.11%
-70.55
Cash Flow From Continuing Investing Activities
194.29
+145.71%
-425.03
-977.91%
-39.43
+44.11%
-70.55
Net PPE Purchase And Sale
-0.63
+35.19%
-0.97
-1442.86%
-0.06
-1.61%
-0.06
Purchase Of PPE
-0.63
+35.19%
-0.97
-1442.86%
-0.06
-1.61%
-0.06
Sale Of PPE
—
—
—
—
Capital Expenditure
-0.63
+35.19%
-0.97
-1442.86%
-0.06
-1.61%
-0.06
Net Investment Purchase And Sale
195.72
+146.15%
-424.06
-977.16%
-39.37
+44.15%
-70.49
Purchase Of Investment
-310.45
+55.84%
-703.01
-212.55%
-224.93
-51.48%
-148.49
Sale Of Investment
506.16
+81.45%
278.96
+50.33%
185.56
+137.90%
78.00
Net Intangibles Purchase And Sale
—
—
—
0.00
Net Other Investing Changes
-0.80
—
—
—
Financing Cash Flow
308.90
-49.08%
606.67
+354.30%
133.54
+31.01%
101.93
Cash Flow From Continuing Financing Activities
308.90
-49.08%
606.67
+354.30%
133.54
+31.01%
101.93
Net Issuance Payments Of Debt
23.34
0.00
-100.00%
24.74
+24.85%
19.82
Issuance Of Debt
23.34
0.00
-100.00%
24.74
+24.85%
19.82
Repayment Of Debt
—
—
—
—
Long Term Debt Issuance
23.34
0.00
-100.00%
24.74
+24.85%
19.82
Long Term Debt Payments
—
—
—
—
Net Long Term Debt Issuance
23.34
0.00
-100.00%
24.74
+24.85%
19.82
Net Common Stock Issuance
300.50
-52.49%
632.52
+450.02%
115.00
+33.52%
86.13
Common Stock Payments
0.00
+100.00%
-0.01
0.00
—
Repurchase Of Capital Stock
0.00
+100.00%
-0.01
0.00
—
Proceeds From Stock Option Exercised
6.98
-47.95%
13.41
+1170.17%
1.06
-49.30%
2.08
Net Other Financing Charges
-21.92
+44.17%
-39.26
-441.12%
-7.26
-19.01%
-6.10
Changes In Cash
262.08
+458.03%
46.97
+2334.68%
1.93
+105.33%
-36.22
Beginning Cash Position
92.65
+102.81%
45.68
+4.41%
43.75
-45.29%
79.97
End Cash Position
354.73
+282.88%
92.65
+102.81%
45.68
+4.41%
43.75
Free Cash Flow
-241.73
-78.20%
-135.65
-47.06%
-92.24
-36.34%
-67.66
Interest Paid Supplemental Data
6.72
+1.02%
6.65
+98.45%
3.35
+274.53%
0.90
Amortization Of Securities
-6.98
+22.19%
-8.97
-102.39%
-4.43
—
Common Stock Issuance
300.50
-52.49%
632.54
+450.03%
115.00
+33.52%
86.13
Issuance Of Capital Stock
300.50
-52.49%
632.54
+450.03%
115.00
+33.52%
86.13
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
Sale Of Intangibles
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category